Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D known ✓ | O15399 | 1/20 | 0.56 |
| ▸ | GRIN3B known ✓ | O60391 | 1/20 | 0.56 |
| ▸ | GRIN1 known ✓ | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2A known ✓ | Q12879 | 1/20 | 0.56 |
| ▸ | GRIN2B known ✓ | Q13224 | 1/20 | 0.56 |
| ▸ | GRIN2C known ✓ | Q14957 | 1/20 | 0.56 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 1/20 | 0.56 |
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.65 |
| ▸ | GRM8 | O00222 | 1/20 | 0.56 |
| ▸ | GRM6 | O15303 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.56 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.56 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.56 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.56 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2462827 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29401163 | 1.00 | GSR (0.65) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL318746 | 1.00 | GSR (0.65) | GSRGRM8GRM6GRIN2DGRIN3B | |
| Hydrochloric Acid SCHEMBL2398999 | 1.00 | — | — | |
| SCHEMBL34705 | 0.97 | — | — | |
| SCHEMBL288792 | 0.97 | — | — | |
| SCHEMBL34706 | 0.97 | — | — | |
| SCHEMBL29479228 | 0.97 | — | — | |
| Bromide SCHEMBL7013646 | 0.94 | — | — | |
| Bromide SCHEMBL29401581 | 0.94 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10123983-B2 | DNA methyltransferases for the treatment and prevention of arthritis | WASHINGTON UNIVERSITY (US) | 2018-11-13 | — | — | US | claimed |
| US-20170071889-A1 | DNA METHYLTRANSFERASES FOR THE TREATMENT AND PREVENTION OF ARTHRITIS | WASHINGTON UNIVERSITY | 2017-03-16 | — | — | US | claimed |
| CN-102952082-A | Manual synthetic method for tetrahydropyrimidine hydrochloride | JINAN HUANTAI MEDICAL TECHNOLOGY CO LTD | 2013-03-06 | — | — | CN | claimed |
| US-5757408-A | PRINTING IMAGE ON SUBSTRATE COATED WITH AMINO-ACID DERIVATIVE ADDITIVE; QUICK DRYING OF INK, OPTICAL DENSITY, NONCURLING | XEROX CORPORATION (US) | 1998-05-26 | — | — | US | claimed |
| US-5683793-A | Ink jet transparencies | XEROX CORPORATION (US) | 1997-11-04 | — | — | US | claimed |
| US-5589277-A | INK JET PRINTING, AQUEOUS INKS, FAST DRYING | XEROX CORPORATION (US) | 1996-12-31 | — | — | US | claimed |
| EP-0667246-A1 | Recording sheets containing amino acids, hydroxy acids, and polycarboxyl compounds | XEROX CORPORATION (US) | 1995-08-16 | — | — | EP | claimed |
| CN-121758308-B | Preparation method of L-2, 4-diaminobutyric acid dihydrochloride | 山东省农药科学研究院 | 2026-05-19 | — | — | CN | disclosed |
| EP-4698275-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4698516-A1 | PYRROLIDINONE UREA FPR2 AGONISTS | Bristol-Myers Squibb Company (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | NOVO NORDISK AS (DK) | 2025-04-17 | — | — | US | disclosed |
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | NOVO NORDISK A/S (DK) | 2025-02-18 | — | — | US | disclosed |
| WO-1994014437-A1 | PREVENTION AND TREATMENT OF SEPSIS | OPHIDIAN PHARMACEUTICALS, INC. (US) | 1994-07-07 | — | — | WO | disclosed |
| WO-1994012480-A1 | 1,3-DIAZACYCLOALKYL OXIME DERIVATIVES | AKZO NOBEL N.V. (NL) | 1994-06-09 | — | — | WO | disclosed |
| WO-1993014750-A2 | AMINO ACIDS USEFUL AS INHIBITORS OF THE ADVANCED GLYCOSYLATION OF PROTEINS | THE ROCKEFELLER UNIVERSITY (US) | 1993-08-05 | — | — | WO | disclosed |
| US-5171835-A | LHRH antagonists | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 1992-12-15 | — | — | US | disclosed |
| EP-0498941-A2 | Peptide skeletal muscle relaxants | BOC Health Care, Inc. (US) | 1992-08-19 | — | — | EP | disclosed |
| US-4670545-A | Chelating agents for technetium-99M | UNIVERSITY PATENTS, INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4234744-A | Process for the production of aminoacid hydrochlorides/or diaminoacid dihydrochlorides | DEUTSCHE GOLD- UND SILBER SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12227528-B2 | Glucose-sensitive albumin-binding derivatives | ALB, DBI, FABP4 | GRIN2D 4098/4885GRIN3B 3217/4885GRIN1 3888/4885 |
| US-20250171776-A1 | NON-CANONICAL CELL-PENETRATING PEPTIDES FOR ANTISENSE OLIGOMER DELIVERY | MYOF, TNNC1, MTPN | GRIN2D 4692/4885GRIN3B 3794/4885GRIN1 4087/4885 |
| US-20250122226-A1 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | ALB, DBI, FABP4 | GRIN2D 4098/4885GRIN3B 3217/4885GRIN1 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.